Compare Alcon AG (ALC) vs Aon PLC (AON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Aon PLC — how do they compare? Alcon AG trades at $66.79 (market cap $32.69B), while Aon PLC trades at $359.14 (market cap $76.85B). The key difference: Aon PLC is far larger — about 2.4× Alcon AG's market cap, and Aon PLC pays the higher dividend (0.91%). Which is the better fit depends on your goals.
| ALC | AON | |
|---|---|---|
Market Cap | $32.69B | $76.85B |
Sector | Health | Financials |
52-Week High | $92.22 | $375.27 |
52-Week Low | $62.02 | $308.22 |
Enterprise Value | $36.28B | $90.91B |
Dividend Yield | 0.54% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
AON trades at $359.82, up 0.66% with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 22.54% net income margin and 46.82% ROE, supported by revenue growth to $17.18B in 2025. Analyst consensus is a Buy with a $385.50 price target, and the company continues to innovate with initiatives like the Aon DPX platform launch in 2026.
Outlook remains positive driven by AI integration and strategic growth, though risks include debt levels and market volatility. The stock offers upside potential near consensus targets, but investors should monitor execution of the 3x3 plan and competitive pressures in the insurance brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →
